⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL79529 | 1.00 | — | — | |
| SCHEMBL29429406 | 1.00 | — | — | |
| SCHEMBL28088304 | 0.97 | SLC6A2 (0.52) | — | |
| Ethane SCHEMBL27674019 | 0.97 | SLC6A2 (0.52) | — | |
| Bromide SCHEMBL28204005 | 0.97 | SLC6A2 (0.52) | — | |
| Ammonia Solution, Strong SCHEMBL25305692 | 0.97 | SLC6A2 (0.52) | — | |
| SCHEMBL30272419 | 0.97 | SLC6A2 (0.52) | — | |
| SCHEMBL27419215 | 0.97 | SLC6A2 (0.52) | — | |
| Hydrochloric Acid SCHEMBL28095407 | 0.97 | SLC6A2 (0.52) | — | |
| Hydrochloric Acid SCHEMBL19814627 | 0.95 | SLC6A2 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116924976-A | Diaryl heterocyclic amine compound, preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2023-10-24 | — | — | CN | claimed |
| US-20250368643-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250368642-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-12473281-B2 | Synthesis of KRAS G12C inhibitor compound | AMGEN INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-12466825-B2 | Synthesis of KRAS G12C inhibitor compound | AMGEN INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-12391689-B2 | Synthesis of key intermediate of KRAS G12C inhibitor compound | AMGEN INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-12391691-B2 | Synthesis of key intermediate of KRAS G12C inhibitor compound | AMGEN INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250206735-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2025-06-26 | — | — | US | disclosed |
| US-20250206736-A1 | SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2025-06-26 | — | — | US | disclosed |
| US-20250179045-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | CONTINEUM THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| US-20230286939-A1 | IMPROVED CHLORANTRANILIPROLE PROCESS THROUGH USE OF A CRYSTAL INTERMEDIATE | FMC IP TECHNOLOGY GMBH (CH) | 2023-09-14 | — | — | US | disclosed |
| EP-4240730-A1 | 2-PYRIDONES AS THYROID HORMONE RECEPTOR MODULATORS | Aligos Therapeutics, Inc. (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20230192681-A1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. | 2023-06-22 | — | — | US | disclosed |
| WO-2023076167-A1 | INHIBITOR OF BTK AND MUTANTS THEREOF | NEWAVE PHARMACEUTICAL INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| EP-4143242-A1 | ZIEGLER-NATTA (PRO)CATALYST SYSTEMS MADE WITH AZAHETEROCYCLIC COMPOUND | Dow Global Technologies LLC (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20220281869-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | FORMA THERAPEUTICS, INC. | 2022-09-08 | — | — | US | disclosed |
| US-20220220112-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. | 2022-07-14 | — | — | US | disclosed |
| WO-2022099044-A1 | 2-PYRIDONES AS THYROID HORMONE RECEPTOR MODULATORS | ALIGOS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| US-11299491-B2 | Synthesis of key intermediate of KRAS G12C inhibitor compound | AMGEN INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-20220073525-A1 | COMPOSITIONS FOR INHIBITING UBIQUITIN SPECIFIC PROTEASE 1 | FORMA THERAPEUTICS, INC. (US) | 2022-03-10 | — | — | US | disclosed |